Patient Access Network Foundation Opens New Bladder Cancer Patient Assistance Fund
Washington, D.C., (January 2, 2019) - The Patient Access Network (PAN) Foundation today opened a new patient assistance program for people living with bladder cancer. Bladder cancer is the 6th most common type of cancer, representing about 4.7 percent of all new cancers in the U.S. The American Cancer Society estimates that in 2018, there were 81,190 new cases of bladder cancer. Qualifying patients are eligible to receive grants from PAN to pay for the deductibles, co-pays and coinsurance costs associated with their bladder cancer treatment.
“The PAN Foundation is pleased to help remove some of the financial burden for people living with bladder cancer,” said PAN President and CEO Daniel Klein. “Bladder cancer is a devastating illness, and thanks to our generous donors, many patients living with bladder cancer will be able to access the treatment they need so they can focus on improving their health and quality of life.”
Patients who qualify for the PAN Foundation’s Bladder Cancer Assistance Program are eligible to receive $3,400 per year in financial assistance. Eligible patients must be getting treatment for bladder cancer; must reside and receive treatment in the United States; must have Medicare health insurance; and the medication for which they seek assistance must be covered by their insurance and must be listed on PAN’s list of covered medications. In addition, patients must fall at or below 500 percent of the Federal Poverty Level.
Patients, or advocates and caregivers applying on their behalf, can apply for assistance using the PAN Foundation’s online patient portal (www.panapply.org), or by calling 1-866-316-7263, 9 a.m. to 7 p.m. ET, Monday through Friday. To learn about PAN’s more than 70 disease-specific programs, visit www.panfoundation.org.
About the PAN Foundation
The PAN Foundation is an independent, nationwide 501(c)3 organization dedicated to providing help and hope to underinsured patients who are unable to afford the out-of-pocket expenses for their prescribed medications. Since 2004, PAN has provided over $3 billion in financial assistance to nearly one million patients who would otherwise be unable to afford their medications. To learn more, visit www.panfoundation.org.
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.
Maintenance Avelumab Has Similar Efficacy in Real World for Urothelial Cancer
March 5th 2024Patients with metastatic urothelial cancer treated with frontline maintenance therapy with avelumab following platinum-based chemotherapy in the real-world setting had similar outcomes as observed in the JAVELIN Bladder 100 trial.
Key Advances in Cancer Survivorship Toxicity Management
July 15th 2022In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
